<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004284</url>
  </required_header>
  <id_info>
    <org_study_id>199/11703</org_study_id>
    <secondary_id>UTSMC-039510400</secondary_id>
    <nct_id>NCT00004284</nct_id>
  </id_info>
  <brief_title>Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Evaluate the ability of a slow-releasing formulation of neutral potassium
      phosphate to correct hypercalciuria and prevent recurrent stone formation in patients with
      absorptive hypercalciuria.

      II. Evaluate the safety of this treatment. III. Compare the efficacy of potassium phosphate
      to that of potassium citrate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by
      participating institution.

      Patients receive potassium phosphate or potassium citrate tablets twice a day for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1995</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>300</enrollment>
  <condition>Hypercalciuria</condition>
  <condition>Kidney Calculi</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>potassium citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>potassium phosphate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Absorptive hypercalciuria Intestinal hyperabsorption of
        calcium, i.e.: Exaggerated calciuric response to oral calcium load OR Fractional calcium-47
        absorption greater than 0.61 Calciuria greater than 200 mg/day on random and
        calcium-restricted diet Normal or high fasting urinary calcium Normal serum calcium Normal
        serum parathyroid hormone No primary hyperparathyroidism At least 1 calcium oxalate stone
        within the past 3 years No struvite or carbonate apatite stones No noncalcareous stones No
        numerous stones making precise quantitation difficult No renal tubular acidosis
        --Prior/Concurrent Therapy-- No concurrent drug therapy for nephrolithiasis --Patient
        Characteristics-- Creatinine clearance at least 0.7 mL/min per kilogram No hyperkalemia No
        hyperphosphatemia No urinary tract infection Other: No predisposition to hyperkalemia,
        including concurrent use of the following drugs: Potassium-sparing diuretics
        Angiotensin-converting enzyme inhibitors Nonsteroidal anti-inflammatory drugs No active
        peptic ulcer disease No chronic diarrhea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Y. C. Pak</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <verification_date>June 2000</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>hypercalciuria</keyword>
  <keyword>nephrolithiasis</keyword>
  <keyword>rare disease</keyword>
  <keyword>renal and genitourinary disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calculi</mesh_term>
    <mesh_term>Hypercalciuria</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
    <mesh_term>Potassium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

